Patent: 9,090,633
✉ Email this page to a colleague
Summary for Patent: 9,090,633
| Title: | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| Abstract: | The invention discloses 4-(arylamino)selenophenopyrimidine derivatives of formula (I), hydrates, solvates, isomers, or pharmaceutically acceptable salts thereof; process for their preparation and methods of treating or inhibiting or controlling a cell proliferative disorders, particularly cancer using said compounds. Pharmaceutical compositions comprising 4-(arylamino)selenophenopyrimidine derivatives of formula (I) are useful for the treatment, inhibition, or control of cancer. ##STR00001## |
| Inventor(s): | Kasina; Sudhakar (Mercer Island, WA), Gokaraju; Ganga Raju (Vijayawada, IN), Somepalli; Venkateswarlu (Vijayawada, IN), Gokaraju; Rama Raju (Vijayawada, IN), Gokaraju; Venkata Kanaka Ranga Raju (Vijayawada, IN), Bhuphatiraju; Kiran (Vijayawada, IN), Golakoti; Trimurtulu (Vijayawada, IN), Sengupta; Krishanu (Vijayawada, IN), Alluri; Venkata Krishna Raju (Vijayawada, IN) |
| Assignee: | Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) |
| Application Number: | 13/912,431 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,090,633
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-11-18 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-11-18 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2030-11-18 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
